Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
Body composition imaging expertise you can rely on.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
A new study published in The Journal of Nuclear Medicine demonstrates the use of [¹⁸F]BCPP-EF PET imaging to measure mitochondrial complex I (MC1) density in both the heart and brain of individuals with Friedreich ataxia (FA). Developed through a collaboration between Pfizer and Perceptive, the study includes both murine and human data and highlights MC1 as a promising noninvasive biomarker for disease monitoring and potential therapeutic response.
This work exemplifies how advanced preclinical and translational imaging methods can support biomarker discovery and clinical development in rare diseases. Learn more about our capabilities in preclinical imaging that support this type of research.
Why Read this Publication:
